Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953326 · ClinicalTrials.gov registry record · Phase 1
HeartPhone Cancer Survivors Trial 2019
A Phase 1 study, sponsored by Penn State University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03953326 is a Phase 1 study that was terminated before completion, run by Penn State University. The registered enrollment target is 2 participants.
The verdict
NCT03953326, a Phase 1 study, was terminated before completion, sponsored by Penn State University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a behavioral study that will examine changes in physical activity and vascular health in response to a digital tool (app) that will appear on participant's lock screen of their Android phone. Participants will be asked to use this app for 3 months and to wear a Fitbit device continuously throughout the study. Participants will be asked to complete questionnaires, participate in fitness testing and measures of cardiovascular health at 3 months and 6 months after baseline assessments. The hypothesis is that exposure to the app will lead to increased physical activity volume and improved microvessel function.
Interventions
- DRUG Acetylcholine
- DRUG Sodium Nitroprusside
- BEHAVIORAL HeartPhone app
- DRUG L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-04-23 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03953326
The ClinicalTrials.gov registry entry for NCT03953326 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Penn State University, which has 219 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Acetylcholine is the first listed.
NCT03953326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03953326 about?
NCT03953326 is a clinical study titled "HeartPhone Cancer Survivors Trial 2019". This is a behavioral study that will examine changes in physical activity and vascular health in response to a digital tool (app) that will appear on participant's lock screen of their Android phone. Participants will be asked to use this app for 3 months and to wear a Fitbit device continuously thr...
What is the current status of trial NCT03953326?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-04-23. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03953326?
The interventions under investigation include: Acetylcholine (DRUG), Sodium Nitroprusside (DRUG), HeartPhone app (BEHAVIORAL), L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester (DRUG).
Who is sponsoring clinical trial NCT03953326?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.